Pharmacologic Management of Hepatic Encephalopathy.

Noah Y Mahpour, Lauren Pioppo-Phelan, Mishal Reja, Augustine Tawadros, Vinod K Rustgi

Journal: Clinics in liver disease 2021;24(2):231-242

PMID: 32245530

Full Text on Elsevier Science View on PubMed

Abstract

Pharmacologic management of hepatic encephalopathy includes a broad range of therapies. This article covers the specific mainstays of therapies, such as antimicrobials and laxatives, with an established evidence base. This article also covers newer modalities of therapies, such as fecal microbiota transplant, probiotics, bioartificial support systems, small molecular therapies such as l-ornithine l-aspartate, branched chain amino acids, l-carnitine, zinc, and other forms of therapy currently under review.

Address: Department of Internal Medicine, Robert Wood Johnson School of Medicine, 1 Robert Wood Johnson Place, New Brunswick, NJ 08901, USA.; Center for Liver Diseases and Liver Masses, Robert Wood Johnson School of Medicine, MedEd Building, Room 466, 1 Robert Wood Johnson Place, New Brunswick, NJ 08901, USA. Electronic address: [email protected].

DOI: 10.1016/j.cld.2020.01.005

Link outs

Free resources

Medical:

https://medlineplus.gov/antibiotics.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Acarbose, Amino Acids, Branched-Chain, Anti-Bacterial Agents, Dipeptides, Fecal Microbiota Transplantation, Flumazenil, GABA Modulators, Glycerol, Glycoside Hydrolase Inhibitors, Hepatic Encephalopathy, Humans, Lactulose, Laxatives, Phenylbutyrates, Probiotics, Rifaximin